NCT02635035 - Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

January 9, 2019

Study Completion Date

January 9, 2019

Conditions

Attention Deficit DisorderAttention Deficit Hyperactivity Disorder

Interventions

DRUG

Lisdexamfetamine

Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment of attention-deficit hyperactivity disorder. The initial adult dosage is 30mg with allowed adjustments in increments of 10mg or 20mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20mg with a maximum dose of 70mg.

DRUG

Placebo

Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.

Trial Locations (2)

10016

Mount Sinai School of Medicine, New York

New York University School of Medicine, New York